title: The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro.
abstract: The use of oncolytic viruses has received considerable attention in recent years and many viruses have proved to be effective against a variety of cancer models and a few are currently being used in clinical trials. However, the possible emergence and outcome of virus-resistant tumour cells has not been addressed. We previously reported the effective use of reovirus against lymphoid malignancies, including the Burkitt's lymphoma cell line Raji. Here we isolated in vitro persistently infected (PI) Raji cells, and cells 'cured' of persistent reovirus infection ('cured' cells). Both PI and cured Raji cells resisted reovirus infection and cell killing in vitro. In vivo, the PI cells were non-tumorigenic in SCID mice, but cured cells regained the parental cells' ability to form tumours. Tumour xenografts from the cured cells, however, were highly susceptible to reovirus oncolysis in vivo. This susceptibility was due to the proteolytic environment within tumours that facilitates reovirus infection and cell killing. Our results show that persistent infection by reovirus impedes tumour development and that although PI cells cleared of reovirus are tumorigenic, they are killed upon rechallenge with reovirus. Both the PI and cured states are therefore not likely to be significant barriers to reovirus oncolytic therapy.
authors.affiliation: Department of Medical Sciences, University of Calgary, Calgary, Alberta, Canada.
authors.forename: T
authors.initials: T
authors.lastname: Alain
authors.forename: M
authors.initials: M
authors.lastname: Kim
authors.forename: R N
authors.initials: RN
authors.lastname: Johnston
authors.forename: S
authors.initials: S
authors.lastname: Urbanski
authors.forename: A E
authors.initials: AE
authors.lastname: Kossakowska
authors.forename: P A
authors.initials: PA
authors.lastname: Forsyth
authors.forename: P W K
authors.initials: PW
authors.lastname: Lee
mesh_terms: D000818:Animals; D002051:Burkitt Lymphoma / Q000473:pathology / Q000628:therapy* / Q000821:virology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D006801:Humans; D007930:Leucine / Q000031:analogs & derivatives / Q000494:pharmacology; D012089:Mammalian orthoreovirus 3 / Q000187:drug effects / Q000502:physiology; D051379:Mice; D016513:Mice, SCID; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000187:drug effects / Q000502:physiology*; D013997:Time Factors; D014771:Virion / Q000187:drug effects / Q000502:physiology; D023041:Xenograft Model Antitumor Assays
chemical_list: D015853:Cysteine Proteinase Inhibitors; D007930:Leucine; C108192:aloxistatin